Vaidya Sane Ayurved Laboratories Limited (NSE:MADHAVBAUG)

Market Cap	1.79B -38.2%
Revenue (ttm)	1.07B +19.0%
Net Income	89.87M +25.9%
EPS	8.04 +38.4%
Shares Out	10.52M
PE Ratio	21.14
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,800
Open	173.95
Previous Close	165.95
Day's Range	169.95 - 174.20
52-Week Range	150.00 - 335.00
Beta	0.44
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2026

About NSE:MADHAVBAUG

Vaidya Sane Ayurved Laboratories Limited, together with its subsidiaries, engages in the research, development, and sale of ayurvedic medicines and products in India. It operates through Sale of Product and Hospital Activity segments. The company sells medicines for arthritis and joint pains, cholesterol, diabetes, digestive, acidity, gastric, dyslipidemia, fever, cough, cold, general tonic, heart disease, hypertension/high blood pressure, liver, low glycemic index atta, obesity/weight management, piles and renal, skin, and wounds; and diet box...

• Industry: Medical Care Facilities
• Sector: Healthcare
• Founded: 1999
• Employees: 636
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: MADHAVBAUG

Financial Performance

In fiscal year 2026, NSE:MADHAVBAUG's revenue was 1.07 billion, an increase of 18.99% compared to the previous year's 898.47 million. Earnings were 89.87 million, an increase of 25.93%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 21, 2026

Data Sources Report a data error